First, the line we will not cross — when to call 988 or 911

If you are reading this because you are in crisis right now, please stop reading and reach out for emergency help. Call or text 988 to reach the Suicide and Crisis Lifeline. Call 911 if you have a plan, the means, or any sense that you may not be safe. Go to the nearest emergency room. Tell someone you trust where you are.

We are a ketamine clinic. We are not an emergency department. Ketamine is not a substitute for inpatient stabilization, a crisis bed, or the kind of moment-to-moment safety planning that an emergency psychiatric team provides. Anyone telling you otherwise is selling you something we do not want to sell.

Once the immediate crisis is contained — once you are medically safe and have an established psychiatric team coordinating your care — that is the window in which a careful conversation about ketamine becomes appropriate. Not before.

Why suicidal ideation in bipolar is different

Bipolar disorder carries one of the highest lifetime suicide risks of any psychiatric condition. Estimates from large cohort studies place the lifetime risk of suicide attempt around 30 to 40 percent in bipolar I and II combined, with a completed-suicide rate that is roughly 10 to 15 times the general population. The depressive pole of bipolar illness, particularly mixed features, is when most of that risk concentrates.

What makes bipolar suicidal ideation clinically distinct is the speed and the layering. Mood can shift in days. Mixed states — the simultaneous presence of depressive hopelessness and manic-spectrum agitation — are particularly dangerous because they combine the wish to die with the energy to act. Standard antidepressants can take six to eight weeks to work, and in some bipolar patients they can destabilize mood further.

This is the gap that ketamine has been studied to address: rapid action in a window where conventional pharmacology is too slow, and where the consequences of waiting are not abstract. Ketamine is FDA-approved as an anesthetic; its use for suicidal ideation in bipolar disorder is off-label.

Wilkinson 2018: the IPD meta-analysis in plain English

The most rigorous piece of evidence on ketamine and suicidal ideation comes from Wilkinson and colleagues, published in 2018 in the American Journal of Psychiatry. This was an individual participant data (IPD) meta-analysis — meaning the authors did not just pool published averages, they pulled the patient-level data from ten randomized controlled trials and re-analyzed it as one dataset of 167 patients.

The headline finding: a single intravenous dose of ketamine produced rapid, statistically significant reductions in suicidal ideation within 24 hours of administration. The benefit was sustained out to one week in many patients. Effect sizes ranged from 0.48 to 0.85 across the various suicidal-ideation rating scales used, which in clinical-trial terms is a moderate-to-large effect.

Two details from the paper matter for the bipolar question. First, the dataset included both unipolar and bipolar depressed patients; the anti-suicidal signal held in the combined group. Second, the reduction in suicidal ideation was only partially explained by ketamine's overall antidepressant effect. In other words, ketamine appeared to act on suicidal thinking through pathways that are at least somewhat distinct from the pathways by which it lifts mood.

That is a meaningful clinical observation. It suggests that the anti-suicidal effect is not just a downstream consequence of mood improvement — it may be its own phenomenon. It also means a patient could in principle experience reduced suicidal intensity even if the broader depressive picture takes longer to shift.

Diazgranados 2010 and the bipolar-specific evidence

Before Wilkinson pooled the data, Diazgranados and colleagues at the NIH ran the first randomized controlled trial of ketamine specifically in treatment-resistant bipolar depression, published in 2010 in Archives of General Psychiatry. Patients were maintained on a therapeutic dose of lithium or valproate, and ketamine was added on as a single IV dose.

Within 40 minutes of infusion, 56 percent of ketamine recipients met the threshold for response, defined as a 50 percent or greater reduction on the Montgomery-Asberg Depression Rating Scale (MADRS). The placebo arm did not show comparable change. A 2012 replication by Zarate and colleagues reproduced the rapid antidepressant effect in a similar bipolar population.

Two patients across the Diazgranados study, one in each arm, developed manic-like symptoms during the trial. That is a small absolute number from a small trial, but the signal is the point: ketamine is a glutamatergic agent given to patients with a mood-cycling illness, and emergent activation is a real if uncommon risk that needs to be screened for and monitored.

The bipolar-specific dataset is smaller than the unipolar dataset. Research suggests the rapid anti-depressant and anti-suicidal effects extend to bipolar populations, but the evidence base is thinner, and clinicians and patients should weigh that honestly.

Spravato's MDSI label vs. off-label IV ketamine in bipolar

In 2020 the FDA expanded the label for Spravato (esketamine) nasal spray to include adjunctive treatment of major depressive disorder with acute suicidal ideation or behavior, often abbreviated MDSI. This was the first time a rapid-acting anti-suicidal indication appeared on a U.S. drug label.

The MDSI indication is for MDD — unipolar major depressive disorder — not bipolar disorder. The Spravato prescribing information does not extend the indication to bipolar I or bipolar II. A bipolar patient receiving Spravato for acute suicidal ideation is, technically, being treated outside the label.

IV racemic ketamine for any psychiatric purpose is also off-label. It is supported by the published research described above, by the clinical practice of academic mood-disorder centers, and by professional guidance documents from groups including the American Psychiatric Association task force on ketamine. It is not, however, FDA-approved for depression or for suicidal ideation in any population. For more on the regulatory picture, see our explainer on the FDA and ketamine, and on the differences between the two formulations, our piece on ketamine vs. Spravato.

What this means in practice: a careful clinic discussing ketamine for bipolar suicidal ideation is having an off-label conversation. The conversation should be explicit about that, about the supporting evidence, and about the limits of that evidence.

The mania risk — and how careful clinics screen for it

Any antidepressant intervention in bipolar disorder carries some risk of treatment-emergent mania, hypomania, or mixed activation. With ketamine, the published rate is low but not zero. In Diazgranados 2010, one patient out of sixteen on ketamine showed manic-like symptoms; the same was true for one patient on placebo, which is part of why the bipolar mania question requires larger datasets to resolve.

What careful clinics do in response is screen, coordinate, and monitor:

Marla Peterson, CRNA, oversees every infusion at Music City Ketamine and provides anesthesia-level monitoring during each session. The mania question, though, is a between-session question as much as an in-session one, and your psychiatrist remains the central voice on whether and how to continue.

What integrated bipolar + ketamine care looks like

For a bipolar patient considering ketamine for the suicidal-ideation component of their illness, the structure of good care looks something like this. There is an established psychiatric team — psychiatrist, often a therapist, sometimes a case manager — that owns the longitudinal care. Acute crises are routed through 988, 911, or an emergency room, not through us. A current safety plan exists and is reviewed regularly. Mood stabilizers are in place at therapeutic doses. The ketamine clinic is a coordinated adjunct, not a stand-alone solution.

Within that structure, ketamine can serve a specific role: a rapidly acting agent that may reduce suicidal ideation intensity within hours and may give a patient and a treatment team a wider window in which longer-acting interventions can do their work. That is a meaningful contribution. It is also a narrow one, and overstating it would be dishonest.

If you want to read further into the related pieces of this picture, our articles on ketamine for suicidal ideation and ketamine for bipolar depression go into more detail on each side of the question. Ketamine for treatment-resistant depression covers the broader treatment-resistant context, and our top-level pages on suicidal ideation and depression describe how we approach these conditions in general.

Honest expectations

Research suggests ketamine can reduce suicidal ideation rapidly in the right patients, including a meaningful proportion of bipolar patients, but the evidence base in bipolar is thinner than in unipolar depression and the response is not universal. Ketamine does not eliminate the underlying illness. It does not replace a psychiatrist, a therapist, mood stabilizers, sleep, or the daily work of a recovery plan. Insurance coverage for ketamine in this context is limited, and IV sessions at Music City Ketamine are $475 each. We are transparent about that from the first conversation. Never start, stop, or adjust your psychiatric medications without consulting your prescribing provider.